Author:
Sawicki-Wrzask Dominik,Thomsen Mikael,Bjerrum Ole J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference29 articles.
1. Pourkavoos N. Unique risks, benefits, and challenges of developing drug-drug combination products in a pharmaceutical industrial setting. Comb Prod Ther. 2012;2:2.
2. European Medicines Agency. CHMP/EWP/240/95 rev 1—guideline on clinical development of fixed combination medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003686.pdf. Published 2009. Accessed February 2014.
3. Podolsky SH, Greene JA. Combination drugs: hype, harm, and hope. N Engl J Med. 2011;365:488–491.
4. Bjerrum OJ, Gautam Y, Honoré PH, Vana V. Drug-drug combinations revisited. Eur J Hosp Pharm. 2014;21:8–12.
5. Lehár J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27:659–666.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献